Affordable Access

deepdyve-link
Publisher Website

High-dose biotin in progressive multiple sclerosis: A prospective study of 178 patients in routine clinical practice.

Authors
  • Couloume, Laura1
  • Barbin, Laetitia2
  • Leray, Emmanuelle3
  • Wiertlewski, Sandrine4
  • Le Page, Emmanuelle5
  • Kerbrat, Anne5
  • Ory, Solenn5
  • Le Port, Damien5
  • Edan, Gilles5
  • Laplaud, David-Axel6
  • Michel, Laure7
  • 1 Service de Neurologie, CHU Nantes, Nantes, France. , (France)
  • 2 CIC0004 Inserm, Nantes, France. , (France)
  • 3 Univ Rennes, EHESP, REPERES (Pharmacoepidemiology and health services research)-EA 7449, Rennes, France. , (France)
  • 4 Service de Neurologie, CHU Nantes, Nantes, France/CIC0004 Inserm, Nantes, France. , (France)
  • 5 Univ Rennes, CHU Rennes, Neurology, Centre d'Investigation Clinique de Rennes (CIC Inserm 1414), Rennes, France. , (France)
  • 6 Service de Neurologie, CHU Nantes, Nantes, France/CIC0004 Inserm, Nantes, France/Centre de Recherche en Transplantation et Immunologie (CRTI), Inserm U1064, Nantes, France/Université de Nantes, Nantes, France. , (France)
  • 7 Service de Neurologie, CHU Pontchaillou, Rennes, France; Univ Rennes, CHU Rennes, Neurology, Centre d'Investigation Clinique de Rennes (CIC Inserm 1414), Rennes, France; Unité Mixte de Recherche (UMR) S1236, INSERM, University of Rennes, Etablissement Français du Sang, Rennes, France/Suivi Immunologique des Thérapeutiques Innovantes, Centre Hospitalier Universitaire de Rennes, Etablissement Français du Sang, Rennes, France. , (France)
Type
Published Article
Journal
Multiple sclerosis (Houndmills, Basingstoke, England)
Publication Date
Dec 01, 2020
Volume
26
Issue
14
Pages
1898–1906
Identifiers
DOI: 10.1177/1352458519894713
PMID: 31845825
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

A recent controlled trial suggested that high-dose biotin supplementation reverses disability progression in patients with progressive multiple sclerosis. To analyze the impact of high-dose biotin in routine clinical practice on disability progression at 12 months. Progressive multiple sclerosis patients who started high-dose biotin at Nantes or Rennes Hospital between 3 June 2015 and 15 September 2017 were included in this prospective study. Disability outcome measures, patient-reported outcome measures, relapses, magnetic resonance imaging (MRI) data, and adverse events were collected at baseline, 6, and 12 months. A total of 178 patients were included. At baseline, patients were 52.0 ± 9.4 years old, mean Expanded Disability Status Scale (EDSS) score was 6.1 ± 1.3, mean disease duration was 16.9 ± 9.5 years. At 12 months, 3.8% of the patients had an improved EDSS score. Regarding the other disability scales, scores either remained stable or increased significantly. In total, 47.4% of the patients described stability, 27.6% felt an improvement, and 25% described a worsening. Four patients (2.2%) had a relapse. Of the 74 patients (41.6%) who underwent an MRI, 20 (27.0%) had new T2 lesions, 8 (10.8%) had gadolinium-enhancing lesions. Twenty-five (14%) reported adverse event. In this study, high-dose biotin did not seem to be associated with a clear improvement in disability.

Report this publication

Statistics

Seen <100 times